Skip to content

Viridian Therapeutics, Inc. VRDN Remeasurement of right-of-use asset and lease liability for lease modifications

Remeasurement of right-of-use asset and lease liability for lease modifications at other companies

Andersen Group
 logo
Andersen Group ANDG
-$437.75K
Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.12M
Lyft, Inc. logo
Lyft, Inc.LYFT
-$3.66M-618%
Eastern Bankshares, Inc. logo
Eastern Bankshares, Inc.EBC
$2.46M+48.3%
Lemonade logo
LemonadeLMND
$775K
Highwoods Properties logo
Highwoods PropertiesHIW
$0-100%

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%

Profitability

See full
Gross margin36.3%
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept vrdn:RemeasurementOfOperatingLeaseRightOfUseAssetsForLeaseModifications.

The official record: Viridian Therapeutics, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s remeasurement of right-of-use asset and lease liability for lease modifications.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s remeasurement of right-of-use asset and lease liability for lease modifications?
Viridian Therapeutics, Inc. (VRDN) reported remeasurement of right-of-use asset and lease liability for lease modifications of $0 in Q4 2025.
How has Viridian Therapeutics, Inc.'s remeasurement of right-of-use asset and lease liability for lease modifications changed year-over-year?
Viridian Therapeutics, Inc.'s remeasurement of right-of-use asset and lease liability for lease modifications decreased by 100.0% year-over-year, from $209.25K to $0.
What is the long-term trend for Viridian Therapeutics, Inc.'s remeasurement of right-of-use asset and lease liability for lease modifications?
Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s remeasurement of right-of-use asset and lease liability for lease modifications has grown at a -100.0% compound annual growth rate (CAGR), from $448K to $0.
What does remeasurement of right-of-use asset and lease liability for lease modifications mean?
This metric represents non-cash adjustments to the carrying value of right-of-use assets and corresponding lease liabilities resulting from modifications to existing lease agreements. It reflects changes in lease terms, such as extensions, terminations, or adjustments to payment structures that require a revaluation of the lease obligation. Monitoring this helps investors understand the impact of real estate or equipment strategy shifts on the balance sheet without immediate cash flow implications.